 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Studien |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Zusammenfassungen ausgewählter Studien The role of bisphosphonates in breast and prostate cancers Janet E. Brown, Helen Neville-Webbe and Robert E. Coleman Endocrine-Related Cancer (2004) 11; 207-224.
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with Zoledronic acid Meletios A. Dimopoulos, Efstathios Kastritis, Athanasios Agnostopoulos, Ioannis Melakopoulos, Dimitra Gika, Lia A. Moulopoulos, Christina Bamia, Evangelos Terpos, Konstantinos Tsionos, Aristotelis Bamias Haematologica/The Hematology Journal 2006; 91 (7) 970-973.
Kieferosteonekrosen (Osteonecrosis of the Jaw)
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer Bruce E. Hillner, James N. Ingle, Rowan T. Chlebowski, Julie Grabow, Gary C. Yee, Nora A. Janjan, Jane A. Cauley, Brent A. Blumenstein, Kathy S. Albain, Allan Lipton, and Susan Brown Journal of Clinical Oncology, Vol 21, No 21 (November 1), 203: pp 4042-4057
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients Kostas Zervas, Evgenia Verrou, Zisis Teleioudis, Konstantinos Vahtsevanos, Anastasia Banti, Dimitra Mihou, Dimitris Krikelis, Evangelos Terpos British Journal of Haematology 2006, 134, 620-623
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma Martha Q. Lacy, Angela Dispenzieri, Morie A. Gertz, Philip R. Greipp, Kimberly L. Gollbach, Suzanne R. Hayman, Shaji Kumar, John A. Lust, S. Vincent Rajkumar, Stephen J. Russell, Thomas E. Witzig, Steven R. Zeldenrust, David Dingli, P. Lief Bergsagel, Rafael Fonesca, Craig B. Reeder, A. Keith Stewart, Vivek Roy, Robert J. Dalton, Alan B. Carr, Deepak Kademani, Eugene E. Keller, Cristopher F. Vizzi, Robert A. Kyle Mayo Clin Proc., August 2006; 81 (8):1047-1053
Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia Tony Mavrokokki, Andrei Cheng, Brien Stein, Alastair Goss J. Oral Maxillofac Surg 65:415-423, 2007
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK Julian F. Guest, John P. Clegg, Alison M. Davie and Eugene McCloskey Current Medical Research And Opinion, Vol. 21, No.5, 2005, 805-815
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients Samantha Pozzi, Raffaela Marcheselli, Stefano Sacchi, Luca Baldini, Francesco Angrilli, Elsa Pennese, Giovanni Quarta, Caterina Stelitano, Giuseppe Caparotti, Stefano Luminari, Pellegrino Musto, Donato Natale, Chiara Broglia, Angela Cuoghi, Daniele Dini, Paolo di Tonno, Giovanni Leonardi, Graziano Pianezze, Vincenzo Pitini, Giuseppe Polimeno, Luisa Ponchio, Luciano Masini, Maurizio Mussi, Mauro Spriano, & Giuseppe Pollastri, On Behalf Of The Gruppo Italiano Studio Linfomi Leukemia & Lymphoma, January 2007; 48(1): 56 - 64
Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients with Cancer S. Ruggiero, J. Gralow, R. E. Marx, A. O. Hoff, M. M. Schubert, J. M. Huryn, B. Toth, K. Damato, V. Valero Journal of Oncology Practice, Volume 2; Issue 1, January, 2006: S. 7-14
From Bench to Bedside R. Graham G. Russell Annals New York Academy Of Sciences 1068:367-401 (2006)
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws S.-B. Woo, J.W. Hellstein, J. R. Kalmar Annals of Internal Medicine 2006; 144:753-761
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
